Status:
COMPLETED
Clinical Validation of InferRead Lung CT.AI
Lead Sponsor:
Infervision
Conditions:
Lung Cancer
Eligibility:
All Genders
55-75 years
Brief Summary
Lung cancer is the second most common cause of cancer-related death in men and women. Early pulmonary nodule screening is an effective means to prevent lung cancer, which is no less important than the...
Eligibility Criteria
Inclusion
- Lung cancer screening eligible patients
Exclusion
- \-
Key Trial Info
Start Date :
January 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2019
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04119960
Start Date
January 10 2019
End Date
October 30 2019
Last Update
July 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201